GDF-15 and colorectal cancer. Comparison between GDF-15, CA19.9 and CEA AT diagnosis von Castillo Perez, C., Tahiri Bachiri, N., Rodriguez Alonso, L., Cebrian Ballesteros, M., Torrubia Dodero, B.

Volltext

T101 HE4 and heart failure. A novel biomarker? von Castillo Perez, C., Cebrian Ballesteros, M., Torrubia Dodero, B., Rodriguez Alonso, L.

Volltext

P0936 Switch from intravenous to subcutaneous infliximab: first subcutaneous dose and cumulative area under curve von Padulles-Zamora, N, Cleries Rovira, P, Alonso Moreno, M, Rodriguez Moranta, F, Ruiz Cerulla, A, Rodriguez Alonso, L, Muñoz Bolaño, M, Guardiola Capon, J

Volltext

Meta-Analysis and Validation of a Colorectal Cancer Risk Prediction Model Using Deep Sequenced Fecal Metagenomes von Obón-Santacana, Mireia, Mas-Lloret, Joan, Bars-Cortina, David, Criado-Mesas, Lourdes, Carreras-Torres, Robert, Díez-Villanueva, Anna, Moratalla-Navarro, Ferran, Guinó, Elisabet, Ibáñez-Sanz, Gemma, Rodríguez-Alonso, Lorena, Mulet-Margalef, Núria, Mata, Alfredo, García-Rodríguez, Ana, Duell, Eric J, Pimenoff, Ville Nikolai, Moreno, Victor

Volltext

OP37 Effect of the HLA-DQA105 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU von Guardiola Capón, J, Iborra, M, Padró, A, de la Peña, L, Serra, K, Martin-Arranz, M D, Domènech, E, Fernandez, A, Mesonero, F, Gonzalez-Muñoza, C, Ferreiro-Iglesias, R, Navarro, P, Martín-Cardona, A, Sicilia, B, Sierra-Ausin, M, Calvet, X, Marquez, L, de Francisco, R, Cañete, F, Gutierrez, A, García-López, S, Rivero, M, Hinojosa, J, Iglesias-Flores, E, Nos, P, Riestra, S, Bosca-Watts, M, Zabana, Y, Castro, B, Barreiro, M, Garcia-Planella, E, Ricart, E, De Francisco, R, Suris, G, Ruiz-Cerulla, A, Rodriguez-Alonso, L, Orobitg, J, Rodríguez-Moranta, F

Volltext

P635 Carriage of the HLA-DQA105 allele is associated with a high risk of loss of response to infliximab in patients with inflammatory bowel disease von Guardiola, J, Rodriguez Alonso, L, Santacana, E, Padró, A, Serra, K, Padullés, N, Ruiz-Cerulla, A, Gilabert, P, Arajol, C, Ibañez-Sanz, G, Camps, B, Orobitg, J, Serracarbasa, A, de la Peña, L, Berrozpe, A, Rodriguez Moranta, F

Volltext

P645 Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients von Guardiola, J, Rodriguez Alonso, L, Padullés, N, Santacana, E, Serra, K, Padulles, A, Ruiz-Cerulla, A, Gilabert, P, Arajol, C, Ibañez-Sanz, G, Camps, B, Colom, H, Bas, J, Morandeira, F, Sanchez, E, Orobitg, J, Rodriguez Moranta, F

Volltext

P318 Association between faecal calprotectin values and infliximab trough levels in inflammatory bowel disease patients von Rodriguez Alonso, L, Serra, K, Santacana, E, Padullés, N, Arajol, C, Gilabert, P, Orobitg, J, Rodríguez-Moranta, F, Colom, H, Padullés, A, Bas, J, Guardiola, J

Volltext

P761 IFX dose-escalation strategy based on a population PK model in IBD patients with secondary loss of response von Guardiola, J, Rodriguez Alonso, L, Serra, K, Santacana, E, Colom, H, Rodríguez-Moranta, F, Gilabert, P, Arajol, C, Sanchez Pastor, E, Bas, J, Padullés, A, Padullés, N

Volltext

P0495 Impact of the HLA DQA105 allele on the efficacy of vedolizumab treatment in inflammatory bowel disease von Castro Torres, S, Ramiro cuenca, L, Rodríguez-Moranta, F, Rodríguez-Alonso, L, Ruiz-Cerulla, A, Sánchez-Pastor, E, Antón-Güell, S, Guardiola Capon, J

Volltext

PKP-010 Impact of the RS1143634 polymorphism of interleukin 1[beta] on infliximab exposure in crohn's disease and ulcerative colitis patients von Santacana, E, Padullés, N, Padullés, A, Padró, A, Rodriguez-Alonso, L, Guardiola, J, Bas, J, Carreres, M, Colom, H

Volltext

P275 Bile acid malabsorption involvement in Crohn's disease symptoms. Its relationship with ROME III criteria von Ruiz-Cerulla, A., Rodriguez-Moranta, F., Rodriguez-Alonso, L., Àrajol, C., Ortega, T. Lobatón, Maisterra, S., Pastor, E. Sanchez, Puig-Calvo, O., Martín-Comín, J., Guardiola, J.

Volltext

P417 Nosocomial Clostridium difficile infection (CDI) incidence in two Spanish referral hospitals. Secular trend during the last decade von Guardiola, J., Ortega, T. Lobaton, Rodriguez-Moranta, F., Alonso, L. Rodriguez, Cancino, C. Parra, Duenas, E.

Volltext

Sistema de Validación para el proceso de fabricación del Ingrediente Farmacéutico Activo Furvina von Cuellar de la Cruz, Mirta E, Alonso Rodríguez, Heidy L, Calvo Alonso, Amalia María

Volltext

P180 A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD) von Ortega, T. Lobaton, Rodriguez-Moranta, F., Guardiola, J., Sanchez-Pastor, E., Alonso, L. Rodriguez, Ruiz-Cerulla, S., Lopez-Garcia, A.

Volltext

P205 A new rapid test for fecal calprotectin (FC) predicts mucosal healing in ulcerative colitis (UC) von Ortega, T. Lobaton, Rodriguez-Moranta, F., Guardiola, J., Lopez-Garcia, A., Sanchez-Pastor, E., Alonso, L. Rodriguez, Maistrerra, S.

Volltext

P1211 A faecal microbial signature, in combination with faecal calprotectin, to optimise endoscopic activity monitoring in Crohn’s Disease von Taboada-López, S, Malagón, M, Amoedo, J, Ramió-Pujol, S, Busquets, D, Bahi, A, Gilabert, P, Rodríguez-Alonso, L, Mañosa, M, Cañete, F, Torres, P F, Morales, V J, Delgado-Guillena, P G, Domenech, E, Guardiola, J, Serra-Pagès, M, Garcia-Gil, L J, Aldeguer, X

Volltext

P202 Performance characteristics of serum FGF19 measurement compared with the Se-HCAT retention test in the diagnosis of bile acid diarrhoea in Crohn’s Disease von Ruiz-Cerulla, A, Blat Serra, R, Sánchez-Pastor, E, Notta, P C, Rodríguez-Alonso, L, Aràjol Gonzalez, C, Serra Nilsson, K, Antón Güell, S, Serrano Santacruz, I, Luque Gómez, A, Aran, J M, Rodríguez-Moranta, F, Guardiola Capon, J

Volltext

P264 Impact of the HLA-DQ105 alelle on the initial response to infliximab in patients with Inflammatory Bowel Disease von Suris Marin, G, Santacana, E, Padullés, N, Padró, A, Serra, K, Ruiz, A, Blat, R, Arajol, C, Sanchez, E, Berrozpe, A, Rodríguez-Alonso, L, Rodríguez-Moranta, F, Guardiola, J

Volltext

P711 Carriage of the HLA-DQA105 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease von Guardiola Capón, J, SERRA, K, Rodríguez-Alonso, L, Santacana, E, Padró, A, Padullés, N, Ruiz-Cerulla, A, Arajol, C, Camps, B, Surís, G, Orobitg, J, Rodríguez-Moranta, F

Volltext